Literature DB >> 8863143

Should a doctor prescribe hormone replacement therapy which has been manufactured from mare's urine?

D Cox1.   

Abstract

Many clinicians are experiencing consumer resistance to the prescription of equine HRT (that is hormone replacement therapy which has been manufactured from mare's urine). In this paper I consider the ethical implications of prescribing these preparations. I decide that patients should have a right to refuse such treatment but also ask whether a prescribing doctor should choose one preparation over another on moral grounds. I determine that there is prima facie evidence to suggest that mares may suffer and that prescription of equine HRT (instead of synthetic oestrogen-oestriol) would therefore have to be justified in terms of either offering greater benefits to the women or offering greater value for money to the health service. I find that there is no substantial evidence to suggest that equine HRT offers unique advantages over and above oestriol. I conclude that it would be preferable for a doctor to recommend the synthetic oestrogen to women who want relief from the symptoms of the menopause and protection from osteoporosis and cardiovascular disease.

Entities:  

Keywords:  Professional Patient Relationship

Mesh:

Substances:

Year:  1996        PMID: 8863143      PMCID: PMC1376997          DOI: 10.1136/jme.22.4.199

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  The effect of a new sequential oestradiol valerate and levonorgestrel preparation on the bone mineral density of postmenopausal women.

Authors:  E F Holland; A T Leather; J W Studd; T J Garnett
Journal:  Br J Obstet Gynaecol       Date:  1993-10

2.  Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators.

Authors:  A A Nabulsi; A R Folsom; A White; W Patsch; G Heiss; K K Wu; M Szklo
Journal:  N Engl J Med       Date:  1993-04-15       Impact factor: 91.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.